Whole pelvis versus prostate-only radiotherapy with or without short course androgen deprivation therapy and mortality risk

被引：0
|
作者：
Braunstein, Lior Z. [1 ]
Chen, Ming-Hui [2 ]
Dosoretz, Daniel E. [3 ]
Salenius, Sharon [3 ]
Katin, Michael [3 ]
Nanda, Akash [4 ]
D'Amico, Anthony V. [5 ,6 ]
机构：
[1] Harvard Radiat Oncol Program, Boston, MA USA
[2] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA
[3] 21st Century Oncol, Ft Myers, FL USA
[4] MD Anderson Canc Ctr Orlando, Orlando, FL USA
[5] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-3438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3438
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk
    Braunstein, Lior Z.
    Chen, Ming-Hui
    Dosoretz, Daniel E.
    Salenius, Sharon A.
    Katin, Michael J.
    Nanda, Akash
    D'Amico, Anthony V.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (06) : 555 - 561
  • [2] Whole-Pelvis Versus Prostate-Only Radiation Therapy and Androgen Deprivation Therapy: Effects on Mortality Risk
    Braunstein, L. Z.
    Chen, M. H.
    Dosoretz, D. E.
    Salenius, S.
    Katin, M.
    Nanda, A.
    D'Amico, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E190 - E191
  • [3] Whole-Pelvic Versus Prostate-Only Radiation Therapy in Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Androgen Deprivation Therapy and Brachytherapy Boost
    Yang, D. D.
    Mahal, B. A.
    Muralidhar, V.
    Martin, N. E.
    King, M.
    Mouw, K.
    Nguyen, P. L.
    Orio, P. F., III
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E150 - E151
  • [4] Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
    Uri Amit
    Yaacov R. Lawrence
    Ilana Weiss
    Zvi Symon
    Radiation Oncology, 14
  • [5] Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
    Amit, Uri
    Lawrence, Yaacov R.
    Weiss, Ilana
    Symon, Zvi
    RADIATION ONCOLOGY, 2019, 14 (1)
  • [6] Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis
    Sandler, Kiri A.
    Cook, Ryan R.
    Ciezki, Jay P.
    Ross, Ashley E.
    Pomerantz, Mark M.
    Nguyen, Paul L.
    Shaikh, Talha
    Tran, Phuoc T.
    Stock, Richard G.
    Merrick, Gregory S.
    Demanes, David Jeffrey
    Spratt, Daniel E.
    Abu-Isa, Eyad I.
    Wedde, Trude B.
    Lilleby, Wolfgang
    Krauss, Daniel J.
    Shaw, Grace K.
    Alam, Ridwan
    Reddy, Chandana A.
    Song, Daniel Y.
    Klein, Eric A.
    Stephenson, Andrew J.
    Tosoian, Jeffrey J.
    Hegde, John V.
    Yoo, Sun Mi
    Fiano, Ryan
    D'Amico, Anthony V.
    Nickols, Nicholas G.
    Aronson, William J.
    Sadeghi, Ahmad
    Greco, Stephen C.
    Deville, Curtiland, Jr.
    McNutt, Todd
    DeWeese, Theodore L.
    Reiter, Robert E.
    Said, Jonathan W.
    Steinberg, Michael L.
    Horwitz, Eric M.
    Kupelian, Patrick A.
    King, Christopher R.
    Kishan, Amar U.
    EUROPEAN UROLOGY, 2020, 77 (01) : 3 - 10
  • [7] Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial
    Parker, Chris C.
    Kynaston, Howard
    Cook, Adrian
    Clarke, Noel W.
    Catton, Charles N.
    Cross, William R.
    Petersen, Peter M.
    Persad, Rajendra A.
    Pugh, Cheryl A.
    Saad, Fred
    Logue, John
    Payne, Heather
    Bower, Lorna C.
    Brawley, Chris
    Rauchenberger, Mary
    Barkati, Maroie
    Bottomley, David M.
    Brasso, Klaus
    Chung, Hans
    Chung, Peter W. M.
    Conroy, Ruth
    Falconer, Alison
    Ford, Vicky
    Goh, Chee L.
    Heath, Catherine M.
    James, Nicholas
    Kim-Sing, Charmaine
    Kodavatiganti, Ravi
    Malone, Shawn C.
    Morris, Stephen L.
    Nabid, Abdenour
    Ong, Aldrich
    Raman, Rakesh
    Rodda, Sree
    Wells, Paula
    Worlding, Jane
    Parulekar, Wendy R.
    Parmar, Mahesh K. B.
    Sydes, Matthew R.
    LANCET, 2024, 403 (10442): : 2416 - 2425
  • [8] CLINICAL TOXICITIES AND DOSIMETRIC PARAMETERS AFTER WHOLE-PELVIS VERSUS PROSTATE-ONLY INTENSITY-MODULATED RADIATION THERAPY FOR PROSTATE CANCER
    Deville, Curtiland
    Both, Stefan
    Hwang, Wei-Ting
    Tochner, Zelig
    Vapiwala, Neha
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : 763 - 772
  • [9] Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study
    Brandell, Jenny Kahlmeter
    Valachis, Antonis
    Ugge, Henrik
    Smith, Daniel
    Johansson, Bengt
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 48
  • [10] Whole Pelvis vs. Prostate Only Irradiation and Mortality in Men with Prostate Cancer Treated with or without Hormonal Therapy
    Nanda, A.
    Chen, M.
    Dosoretz, D.
    Salenius, S.
    Katin, M.
    Ross, R.
    D'Amico, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S565 - S566
12345